Nisa Investment Advisors LLC Raises Stake in Avantor, Inc. (NYSE:AVTR)

Nisa Investment Advisors LLC raised its position in Avantor, Inc. (NYSE:AVTR) by 917.2% during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 20,700 shares of the company’s stock after purchasing an additional 18,665 shares during the period. Nisa Investment Advisors LLC’s holdings in Avantor were worth $436,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds and other institutional investors have also modified their holdings of AVTR. MassMutual Private Wealth & Trust FSB boosted its holdings in Avantor by 99.5% in the fourth quarter. MassMutual Private Wealth & Trust FSB now owns 1,253 shares of the company’s stock valued at $26,000 after purchasing an additional 625 shares in the last quarter. UMB Bank n.a. purchased a new position in shares of Avantor in the 3rd quarter valued at $49,000. GAMMA Investing LLC raised its stake in Avantor by 89.9% during the 3rd quarter. GAMMA Investing LLC now owns 2,715 shares of the company’s stock worth $70,000 after acquiring an additional 1,285 shares in the last quarter. Livforsakringsbolaget Skandia Omsesidigt lifted its position in Avantor by 278.0% in the third quarter. Livforsakringsbolaget Skandia Omsesidigt now owns 5,031 shares of the company’s stock valued at $130,000 after acquiring an additional 3,700 shares during the last quarter. Finally, ORG Wealth Partners LLC acquired a new position in Avantor in the third quarter valued at $139,000. 95.08% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several research firms have recently weighed in on AVTR. Barclays reduced their target price on Avantor from $28.00 to $25.00 and set an “overweight” rating for the company in a report on Friday, October 25th. Robert W. Baird reduced their price objective on Avantor from $27.00 to $26.00 and set an “outperform” rating for the company in a research note on Monday, October 28th. UBS Group restated a “neutral” rating and set a $25.00 target price (down from $29.00) on shares of Avantor in a research report on Friday, January 17th. Wells Fargo & Company reduced their price target on shares of Avantor from $30.00 to $28.00 and set an “overweight” rating for the company in a research report on Monday, October 28th. Finally, Raymond James lowered their price objective on shares of Avantor from $29.00 to $26.00 and set an “outperform” rating on the stock in a research report on Tuesday, January 21st. Three equities research analysts have rated the stock with a hold rating and ten have given a buy rating to the company. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $27.38.

Avantor Trading Down 3.9 %

NYSE:AVTR opened at $21.55 on Thursday. Avantor, Inc. has a 1 year low of $19.59 and a 1 year high of $28.00. The company has a debt-to-equity ratio of 0.84, a quick ratio of 1.06 and a current ratio of 1.54. The stock has a fifty day moving average price of $21.60 and a two-hundred day moving average price of $23.45. The stock has a market capitalization of $14.66 billion, a price-to-earnings ratio of 46.84, a PEG ratio of 3.53 and a beta of 1.28.

Avantor Company Profile

Avantor, Inc engages in the provision of mission-critical products and services to customers in the biopharma, healthcare, education and government, advanced technologies, and applied materials industries in the Americas, Europe, Asia, the Middle East, and Africa. The company offers materials and consumables, such as purity chemicals and reagents, lab products and supplies, formulated silicone materials, customized excipients, customized single-use assemblies, process chromatography resins and columns, analytical sample prep kits, education and microbiology products, clinical trial kits, peristaltic pumps, and fluid handling tips.